Distinct expression of Kaposi’s sarcoma‐associated herpesvirus‐encoded proteins in Kaposi’s sarcoma and multicentric Castleman’s disease
暂无分享,去创建一个
S. Oka | T. Sata | Yuko Sato | H. Katano | D. Matsubara | H. Gatanaga | S. Kimura | K. Saitoh | T. Fujii | Y. Sasao | Yasuhisa Abe
[1] L. Staudt,et al. Clinical Trials and Observations , 2007 .
[2] R. Ricciardi,et al. Processivity factor of KSHV contains a nuclear localization signal and binding domains for transporting viral DNA polymerase into the nucleus. , 2005, Virology.
[3] C. Casper,et al. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care , 2005, British journal of haematology.
[4] M. Du,et al. Pathology of bone marrow in human herpes virus‐8 (HHV8)‐associated multicentric Castleman disease , 2004, British journal of haematology.
[5] A. Wald,et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. , 2004, Blood.
[6] M. Cornelissen,et al. Multicentric Castleman's disease and Kaposi's sarcoma in a cyclosporin treated, HIV-1 negative patient: case report , 2003, BMC blood disorders.
[7] J. Bourhis,et al. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody , 2003, Annals of Hematology.
[8] P. Moore,et al. Viral IL-6-Induced Cell Proliferation and Immune Evasion of Interferon Activity , 2002, Science.
[9] G. Delsol,et al. HHV‐8 infection status of AIDS‐unrelated and AIDS‐associated multicentric Castleman's disease , 2001, Pathology international.
[10] J. Manning,et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy , 2001, Cancer.
[11] S. Pittaluga,et al. Serum viral interleukin-6 in AIDS-related multicentric Castleman disease. , 2001, Blood.
[12] P. Brousset,et al. Detection and characterization of human herpesvirus-8-infected cells in bone marrow biopsies of human immunodeficiency virus-positive patients. , 2001, Human pathology.
[13] B. Chandran,et al. Characterization of Human Herpesvirus 8 ORF59 Protein (PF-8) and Mapping of the Processivity and Viral DNA Polymerase-Interacting Domains , 2000, Journal of Virology.
[14] É. Oksenhendler,et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. , 2000, Blood.
[15] N. Saini,et al. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon-alpha. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] R. Inagi,et al. Human herpesvirus 8‐encoded interleukin‐6 homologue (viral IL‐6) induces endogenous human IL‐6 secretion , 2000, Journal of medical virology.
[17] D. Podzamczer,et al. Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin , 2000, AIDS.
[18] S. Mori,et al. Identification of Antigenic Proteins Encoded by Human Herpesvirus 8 and Seroprevalence in the General Population and among Patients with and without Kaposi's Sarcoma , 2000, Journal of Virology.
[19] S. Mori,et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. , 2000, Virology.
[20] W. Rozenbaum,et al. Quantitative Analysis of Human Herpesvirus 8 Viral Load Using a Real-Time PCR Assay , 2000, Journal of Clinical Microbiology.
[21] M. Corbellino,et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. , 2000, The American journal of pathology.
[22] S. Sakurada,et al. Expression and antigenicity of human herpesvirus 8 encoded ORF59 protein in AIDS‐associated Kaposi's sarcoma , 1999, Journal of medical virology.
[23] H. Satoh,et al. Establishing and characterizing a CD30‐positive cell line harboring HHV‐8 from a primary effusion lymphoma , 1999, Journal of medical virology.
[24] S. Mori,et al. High expression of HHV-8-encoded ORF73 protein in spindle-shaped cells of Kaposi's sarcoma. , 1999, The American journal of pathology.
[25] E. van Marck,et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] M A Fischl,et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] J. Herrada,et al. The Clinical Behavior of Localized and Multicentric Castleman Disease , 1998, Annals of Internal Medicine.
[28] B. Chandran,et al. Identification and characterization of human herpesvirus-8 lytic cycle-associated ORF 59 protein and the encoding cDNA by monoclonal antibody. , 1998, Virology.
[29] G. Gaidano,et al. Association of Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma with expression of the CD138/syndecan-1 antigen. , 1997, Blood.
[30] M. Corbellino,et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. , 1997, The American journal of pathology.
[31] C. Boshoff,et al. Molecular Mimicry of Human Cytokine and Cytokine Response Pathway Genes by KSHV , 1996, Science.
[32] S. Imai. Mouse mammary tumor virus and mammary tumorigenesis in wild mice. , 1996, Pathology international.
[33] M. Yamakawa,et al. Morphology, function and pathology of follicular dendritic cells , 1996, Pathology international.
[34] R. Sun,et al. Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. , 1996, The New England journal of medicine.
[35] I. Sesterhenn,et al. Lymphoid changes of the nasopharyngeal and palatine tonsils that are indicative of human immunodeficiency virus infection. A clinicopathologic study of 12 cases. , 1996, The American journal of surgical pathology.
[36] M. McGrath,et al. Lytic growth of Kaposi's sarcoma–associated herpesvirus (human herpesvirus 8) in culture , 1996, Nature Medicine.
[37] F. Sigaux,et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.
[38] B. Klein,et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. , 1994, The New England journal of medicine.
[39] A. Dalgleish,et al. Kaposi's sarcoma. , 1991, British Journal of Cancer.
[40] A. Stansfeld,et al. An immunohistological and genotypic study of the plasma cell form of Castleman's disease , 1989, Histopathology.
[41] B. Peterson,et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] B. Nathwani,et al. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. , 1985, Human pathology.
[43] P. Banks,et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: Pathological findings in 15 patients , 1983, The American journal of surgical pathology.
[44] E. Robertson,et al. OF KAPOSI ’ S SARCOMA-ASSOCIATED HERPESVIRUS , 2002 .
[45] Y. Shima,et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. , 2000, Blood.
[46] T. Komori,et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. , 1989, Blood.